Edison publishes research on Biotech Growth Trust

RNS Number : 2652F
Biotech Growth Trust PLC (The)
18 February 2015
 

 

London, UK, 18 February 2015

Edison issues research update on The Biotech Growth Trust

 

The Biotech Growth Trust (BIOG) is an established specialist investor in the worldwide biotechnology industry. Biotech has performed strongly in the three years to 31 January, with the benchmark NASDAQ Biotech index producing a total return of 195% and BIOG achieving NAV total returns of 223%. However, the managers point to valuations for major biotech stocks that compare favourably with big pharmaceutical firms, and greater potential earnings growth, as evidence that relative value still remains. Scientific advances and a more favourable regulatory environment are feeding through into a healthy drug pipeline. BIOG's shares currently trade close to par, with buybacks used if the discount to NAV exceeds 6%.

 

For the full report click here.

All reports published by Edison are available to download free of charge from its website.

www.edisoninvestmentresearch.com

 

 

 

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn

www.linkedin.com/company/edison-investment-research

Twitter

www.twitter.com/Edison_Inv_Res

YouTube

www.youtube.com/edisonitv

 

London
+44 (0)20 3077 5700

280 High Holborn

London,
WC1V 7EE

United Kingdom

New York
+1 646 653 7026

245 Park Avenue, 39th Floor

New York, NY 10167
US

Sydney
+61 (0)2 9258 1161

Level 25 Aurora Place
88 Philip Street

Sydney NSW 2000

Australia

Frankfurt
+49 (0)69 78 8076 960

Schumannstrasse
34b

60325 Frankfurt

Germany

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUBPPUPAGCR
Investor Meets Company
UK 100